Abivax (AAVXF) Deferred Taxes (2024 - 2025)
Abivax (AAVXF) posted Deferred Taxes of $795.6 million for Q4 2025, up 2540.97% on a QoQ basis from $30.1 million in Q3 2025, and down 57.77% year-over-year from $1.9 billion in Q4 2024.
Powered by 
Analysis
Abivax (AAVXF) Deferred Taxes (2024 - 2025) Analysis & Trends
Abivax has reported Deferred Taxes for 2 years, with the latest figure at $795.6 million in Q4 2025.
- On a quarterly basis, Deferred Taxes fell 57.77% year-over-year to $795.6 million in Q4 2025; TTM through Mar 2026 was $826.5 million, a 56.13% decrease from a year earlier, with the FY2025 full-year figure at $826.5 million, down 56.13% from the prior year.
- Deferred Taxes was $795.6 million for Q4 2025 at Abivax, up from $30.1 million in the prior quarter.
- The five-year high for Deferred Taxes was $1.9 billion in Q4 2024, with the low at -$179009.8 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.13 Bn | 197.14 Bn | 7.24 Bn | -291.00 Mn |
| 2 | Gilead Sciences | 181.20 Bn | 178.03 Bn | 6.22 Bn | -587.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.23 Bn | 124.38 Bn | 2.84 Bn | -69.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.91 Bn | 74.92 Bn | 3.93 Bn | 194.40 Mn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | - |
| 6 | Moderna | 55.02 Bn | 49.89 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.05 Bn | 30.74 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Biogen | 31.30 Bn | 30.01 Bn | 1.96 Bn | -27.60 Mn |
| 9 | Roivant Sciences | 30.18 Bn | 30.18 Bn | 1.16 Mn | - |
| 10 | Abivax | 10.92 Bn | 10.92 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 795.60 Mn |
| Sep 30, 2025 | 30.13 Mn |
| Jun 30, 2025 | 819,538.81 |
| Mar 31, 2025 | 27,349.00 |
| Dec 31, 2024 | 1.88 Bn |
| Sep 30, 2024 | -179,009.78 |
| Jun 30, 2024 | 268,145.01 |
| Mar 31, 2024 | -27,159.04 |